15,795 Shares in Boston Scientific Co. (NYSE:BSX) Purchased by M&G Plc

M&G PLC purchased a new position in Boston Scientific Co. (NYSE:BSX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 15,795 shares of the medical equipment provider's stock, valued at approximately $1,327,000.

A number of other institutional investors have also recently made changes to their positions in BSX. Capital World Investors boosted its stake in Boston Scientific by 69.9% in the first quarter. Capital World Investors now owns 16,008,085 shares of the medical equipment provider's stock worth $1,096,394,000 after buying an additional 6,588,256 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Boston Scientific by 115.9% in the 2nd quarter. Marshall Wace LLP now owns 6,720,480 shares of the medical equipment provider's stock valued at $517,544,000 after purchasing an additional 3,608,158 shares in the last quarter. Capital Research Global Investors bought a new position in shares of Boston Scientific during the 1st quarter valued at $182,897,000. AustralianSuper Pty Ltd raised its position in Boston Scientific by 4,292.3% in the 3rd quarter. AustralianSuper Pty Ltd now owns 2,676,847 shares of the medical equipment provider's stock worth $224,320,000 after purchasing an additional 2,615,903 shares during the period. Finally, Vanguard Group Inc. raised its position in Boston Scientific by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 127,437,884 shares of the medical equipment provider's stock worth $8,728,221,000 after purchasing an additional 1,988,082 shares during the period. Institutional investors own 89.07% of the company's stock.

Wall Street Analyst Weigh In

BSX has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their price objective on Boston Scientific from $82.00 to $85.00 and gave the stock an "overweight" rating in a report on Thursday, July 25th. Canaccord Genuity Group lifted their price target on Boston Scientific from $88.00 to $98.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a research note on Thursday, October 31st. Stifel Nicolaus lifted their target price on shares of Boston Scientific from $85.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, October 18th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Boston Scientific from $73.00 to $78.00 and gave the company a "hold" rating in a report on Thursday, July 25th. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $93.39.

Insider Buying and Selling

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total value of $585,594.38. Following the transaction, the executive vice president now directly owns 34,748 shares in the company, valued at approximately $2,913,967.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total value of $585,594.38. Following the completion of the sale, the executive vice president now owns 34,748 shares in the company, valued at $2,913,967.28. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the transaction, the chief executive officer now directly owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 309,270 shares of company stock valued at $26,196,718. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Up 1.6 %

NYSE:BSX traded up $1.37 during trading hours on Friday, reaching $88.25. 5,242,205 shares of the company traded hands, compared to its average volume of 7,294,248. Boston Scientific Co. has a 1 year low of $50.84 and a 1 year high of $88.94. The stock has a market capitalization of $130.07 billion, a P/E ratio of 72.93, a P/E/G ratio of 2.55 and a beta of 0.79. The business's 50-day moving average price is $84.61 and its two-hundred day moving average price is $78.93. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion for the quarter, compared to analysts' expectations of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific's revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.50 EPS. Analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.